 Connection
Yuya Hirasawa to Neoplasms
This is a "connection" page, showing publications Yuya Hirasawa has written about Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.588 |
|
|
|
-
Hirasawa Y, Isobe J, Hosonuma M, Tsurui T, Baba Y, Funayama E, Tajima K, Murayama M, Narikawa Y, Toyoda H, Shida M, Sasaki A, Maruyama Y, Amari Y, Mura E, Suzuki R, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Sambe T, Uchida N, Wada S, Kobayashi S, Kiuchi Y, Kuramasu A, Yoshimura K, Tsunoda T. Veillonella and Streptococcus are associated with aging of the gut microbiota and affect the efficacy of immune checkpoint inhibitors. Front Immunol. 2025; 16:1528521.
Score: 0.301
-
Ariizumi H, Shimazui M, Ogawa C, Kaneki M, Saito N, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Hirasawa Y, Shimokawa M, Ohkuma R, Kubota Y, Horiike A, Wada S, Yoshimura K, Murakami K, Tsunoda T. Vinegar intake in patients undergoing immune checkpoint inhibitor therapy: food frequency questionnaire study. Front Immunol. 2025; 16:1640603.
Score: 0.078
-
Hosonuma M, Hirasawa Y, Kuramasu A, Murayama M, Narikawa Y, Toyoda H, Baba Y, Isobe J, Funayama E, Tajima K, Shida M, Hamada K, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Tsunoda T, Yoshimura K. Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit. Cancer Sci. 2024 Mar; 115(3):752-762.
Score: 0.069
-
Hamada K, Isobe J, Hattori K, Hosonuma M, Baba Y, Murayama M, Narikawa Y, Toyoda H, Funayama E, Tajima K, Shida M, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Kuramasu A, Horiike A, Kim YG, Tsunoda T, Yoshimura K. Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor. Front Immunol. 2023; 14:1164724.
Score: 0.065
-
Tsuboya A, Kubota Y, Ishida H, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Sasaki Y, Matsumoto N, Kondo Y, Tomoda Y, Kusuhara H, Fujita KI. Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure. Cancer Chemother Pharmacol. 2021 09; 88(3):543-553.
Score: 0.057
-
Murayama M, Hosonuma M, Kuramasu A, Kobayashi S, Sasaki A, Baba Y, Narikawa Y, Toyoda H, Isobe J, Funayama E, Tajima K, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Hamada K, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kobayashi S, Shimane T, Tsunoda T, Kobayashi H, Kiuchi Y, Yoshimura K. Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody. Sci Rep. 2024 05 17; 14(1):11325.
Score: 0.018
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|